BAB VII

SIMPULAN DAN SARAN

7.1. Simpulan

Hasil penelitian ini dapat disimpulkan bahwa :

1. Pemberian EEDS dapat menurunkan kadar GDS diabetes melitus dibandingkan kelompok kontrol (p *value* : 0.006), terutama pada dosis 300mg/200 gr BB.
2. Pemberian EEDS tidak dapat menurunkan ekpresi VEGF podosit glomerulus secara bermakna diantara kelompok perlakuan dan kontrol (p:0.20;p>0,05). Hal ini dikarenakan expresi VEGF podosit glomerulus dihambat dan belum muncul pada saat pemeriksaan IHC dilakukan. Rata-rata allred score pada masing-masing kelompok, semakin tinggi dosis semakin rendah ekspresi VEGF podosit glomerulus.

7.2. Saran

Penelitian ini perlu disempurnakan oleh peneliti selanjutnya dengan memperhatikan hal-hal sebagai berikut:

1. Ekpresi VEGF pada podosit glomerulus ginjal pasca induksi *streptozotocin* yang diamati pada hari ke-15 pada kelompok kontrol , dengan nilai *allred score* yang lemah.

2. Ekpresi VEGF tidak hanya diamati pada podosit glomerulus tetapi pada tubulus distal dan proksimal ginjal.
3. Pemberian ekstrak daun salam untuk menurunkan gula darah sewaktu perlu dipertimbangkan waktu yang tepat, berapa lama ekstrak daun salam dapat meregulasi gula darah sampai dalam kondisi normal.
4. Terapi untuk memperbaiki disfungsi sel endotel tidak hanya menggunakan antioksidan. Terapi antioksidan dalam konsentrasi yang tinggi baru dapat menurunkan kadar *peroxynitrite.*

DAFTAR PUSTAKA

1. Sunil, K. *et al.*, Aberrant Angiogenesis : The Gateway to Diabetic Complications. *Indian Journal of Endocrinology and Metabolism* XVI (6) (2012).

2. Khamaisi, M. S. B., Vriese, R. I. & Flyvbjerg, A., The Emerging Role of VEGF in Diabetic Kidney Disease. *Nephrol Dialysis Transplant* 18, 1427-1430 (2003).

3. International Diabetes Federation, IDF Diabetes Atlas 5th Edition UPDATE-Country Details Table (2012).

4. Tzouveleki, M. M., Tsartsalis, S. & Tomos, C., Vascular Enothelial Growth Factor (VEGF) in the Pathogenenesis of Diabetic Nephropathy of Type I Diabetes Mellitus. *Current Drug Target* 12, 107-114 (2011).

5. Gavaske *et al.*, VEGF-A Protects the Glomerular Microvasculature in Diabetes. *Diabetes Journal* 61, 2958-2966 (2012).

6. Christhoper, Osmoregulation II. *Animal Sciences Bio 131 with Thometz at Univercity of California-Santa cruz* (2012).

7. Nangaku, M., Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. *Journal American Soc Nephrol* 17, 17-25 (2006).

8. Noh, H. & King, G., The Role of Protein Kinase c activation in Diabetic Nephropathy. *Kidney International* 72, S49-S53 (2007)

9. Kusuma, I. W. *et al.*, Biological Activity and Phytochemical Analysis of Three Indonesian Medicinal Plants, Murraya koenigii, Syzygium polyanthum and Zingiber purpurea. *Acupunct Meridian Stud.* 4 (1), 75-79 (2011).

10. Lelono, R. A. A. & Tachibana, S., Preliminary Studies of Indonesian Eugenia polyantha Leaf Extracts as Inhibitors of Key Enzymes for. *Journal of Medical Sciences* 13 (2), 103-110. (2013).

11. Studiawan, H. & Santosa, M. H., Uji Aktifitas Penurunan Kadar Gula Darah Ekstrak Daun Eugenia Poliantha pada Mencit yang Diinduksi Alloxan. *Kedokteran Hewan* 21 (2), 62-65 (2005).

12. Murnah, Pengaruh ekstrak etanol Mengkudu (Morinda citrifolia L) terhadap Diabetik Nefropati pada Tikus Srague Dawley yang diinduksi streptozotosin dengan kajian VEGF dan mikroalbuminuria. *Tesis Magister Biomedik Undip* (2011).

13. Sulistyoningrum, E. & Setiawati, Phaleria macrocarpha reduces glomerular growth factor expression in alloxan- induced diabetic rats. *Universa Medicina* 32 (2), 71-79 (2013).

14. Nakagawa, T., Kosugi, T., Haneda, M., Rivard, C. J. & Long, D. A., Abnormal Angiogenesis in Diabetic Nephropathy. *Diabetes Journal* 58, 1471-1478 (2009).

15. Brownlee, M., The Pathobiology of Diabetic Complications, A Unifying Mechanism. *American Diabetes Association*, 1615-1625 (2005).

16. Giacco, F. & Brownlee, M., Oxidative Stress and Diabetic Complication. *American Heart Association* (2010).

17. Liu, E. *et al.*, Increased Expression of Vascular Endothelial Growth Factor in Kidney Leads to Progressive Impaiment of Glomerular Functions. *Journal American Society of Nephrology*, 2094-2104 (2007).

18. Schrijvers, B. F. & Vriese, The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. *Kidney International Vol. 65*, 2003-2017 (2004).

19. Tufro, A. & Veron, D., VEGF And Podocytes in Diabetic Nephropathy. *Semin Nephrol* 32 (4), 62-65 (2012).

20. Sharma, V., Pole of Different Molecular Pathways in The Development of Diabetes-Induced Nephropathy. *Diabetes & Metabolism*, 1-7 (2013).

21. Schlingemann, R. O., VEGF Levels in Plasma in Relation to Platelet Activation, Glycemic Control,and Microvascular Complications in Type 1 Diabetes. *Diabetes Care*, 1629–1634 (2013).

22. Sastrawan, I. G. P. & Suwitra, K., Peran Hipoksia pada patogenesis penyakit ginjal. *Journal Penyakit Dalam* 9 (1), 75-84 (2008).

23. Davis, R., Angiotensin II and glucose stimulated extracellular matrix production : mediation by the insulin growth factor(IGF) axis in murine mesangial cell line. *Endocrine* 33, 32-39 (2008).

24. Alsaad, H., Distinguishing diabetes nephropathy from other causes of glomerulosclerosis : an Uptade. *J Clin Pathology* 60, 1-9 (2007).

25. Mcgrower, Biomechemical evaluation of oxidative stress in type I diabetes. *Intech*, 223-248 (2013).

26. Krishan, C. V., Diabetic nephropathy : agressive involment of oxidative stress. *J Pharmacy Educ Res*, 35-41 (2011).

27. Depkes RI, *Materia Medika Indonesia* (Depkes RI, Jakarta, 1980).

28. Yohana Arisandi, N. A., *Khasiat Tanaman Obat* (Pustaka Buku Murah, Jakarta, 2008).

29. Agus Sumono, A. W., The use of bay leaf (Eugenia Polyantha Wight) in dentistry. *Dental Journal*, 3 (2008).

30. Mun'im, A. & Hanani, E., *Fitoterapi Dasar* (Dian Rakyat, Jakarta, 2011).

31. Arora, S., Ojha, S. K. & Vahora, D., Characterisation of Streptozotocin Induced Diabetes Mellitus in Swiss Albino Mice. *Global Journal of Pharmacology* 3 (2), 81-84 (2009).

32. Cao, Z. & Cooper, M. E., Pathogenesis of Diabetic Nephropathy. *Journal of Diabetes Investigation* 2 (4), 243-247 (2011).

33. HAR, L. W. & Ismail, I. S., Antioxidant Activity, Total Phenolic and total flavonoids of Syzygium Polianthum (Wight) Walp Leaves. *Med. Arom. Plants.*, 219-228 (2012).

34. Akbarzadeh, A. *et al.*, Induction of Diabetes By Streptozotocin in Rats. *Indian Journal of Clinical Biochemistry*, 60-64 (2007).

35. Cha, D. R., Kang, Y. S. & Sang Youb Han, Y. H. J. e. a., Vascular Endothelial Growth Factor is Increased During Early Stage of Diabetic Nephropathy in Type II Diabetic Rats. *Journal of Endocrinologi*, 81-84 (2004).

36. Szkudelski, T., The Mechanisme of Alloxan and Streptozotocin Action in B Cell of the Rat Pancreas. *Physiological Research*, 50, 536-546 (2001).

37. Tesch, G., Terri, J. & Allen, T., Methods in Renal Research : Rodent Models of Streptozotocin-Induced Diabetic Nephropathy. *Nephrology*, 261-266 (2007).

38. Sastroasmoro S, I., *Dasar-dasar metodologi penelitian klinis*, 3rd ed. (Sagung Seto, Jakarta, 2008).

39. Melhelm, M., Craven, P., Liachenko, J. & Dubertis, F., α-Lipoic Acid Attenuates Hyperglycemia an Prevents Glomerular Mesangial Matrix Expansion in Diabetes. *Journal of American Society of Nephrology*, 108-116 (2002).

40. Salmon, A., Nea, C. & Steven Harper, D. ., Vascular endotheial growth factor increaes the ultrafiltration coefficient in isolated intact wistar rat glomeruli. *J Physiology*, 141-156 (2006).